Which disease-modifying antirheumatic drug (DMARD) is appropriate for a hypertensive adult with rheumatoid arthritis?

Methotrexate is the Preferred DMARD for Hypertensive Patients with Rheumatoid Arthritis

Methotrexate should be the first-line DMARD for adults with rheumatoid arthritis and hypertension, as it is associated with blood pressure reduction and decreased cardiovascular risk, while leflunomide should be explicitly avoided due to its association with incident hypertension. 1, 2, 3

Guideline-Based Recommendation

Both major international guidelines strongly recommend methotrexate as the preferred initial DMARD for rheumatoid arthritis regardless of comorbidities 1, 2. The 2026 Pan American League of Associations for Rheumatology and 2021 American College of Rheumatology guidelines emphasize:

• Initiate methotrexate as soon as possible after RA diagnosis
• Target dose of at least 15 mg weekly within 4-6 weeks 2
• Switch to subcutaneous administration if oral form causes gastrointestinal intolerance 1, 2

Blood Pressure Effects of Specific DMARDs

Beneficial DMARDs (Lower BP):

• Methotrexate: Associated with significant SBP decline (β = -1.08 mmHg) and DBP decline (β = -0.48 mmHg) over 6 months; users were 9% more likely to achieve optimal BP 3
• Hydroxychloroquine: Showed the greatest BP decline alongside methotrexate 3
• Sulfasalazine: Associated with reduced cardiovascular risk, though less protective than methotrexate 4

Harmful DMARDs (Raise BP):

• Leflunomide: Associated with BP increases and 53% greater risk of incident hypertension compared to methotrexate (HR 1.53,95% CI 1.21-1.91) 3, 5. This drug should be avoided in hypertensive patients.
• Prednisone: Increases BP and hypertension risk in multiple studies 5
• COX-2 inhibitors: Associated with BP variability 5

Neutral DMARDs:

• Biologic DMARDs (TNF inhibitors, abatacept, rituximab): No consistent evidence of increased hypertension risk compared to conventional DMARDs 6, 7
• JAK inhibitors (tofacitinib, baricitinib, upadacitinib): Limited data, though one study noted 13.5% of tofacitinib users developed hypertension 8

Practical Treatment Algorithm

1. Start with oral methotrexate at 15-25 mg weekly with folic acid supplementation
2. If GI intolerance occurs: Switch to subcutaneous methotrexate before abandoning the drug 1, 2
3. If inadequate response after optimization: Add a biologic DMARD (TNF inhibitor, abatacept, rituximab, or IL-6 inhibitor) rather than switching to leflunomide 7
4. Monitor BP closely during the first 6 months, as improvement should be observed 3

Critical Caveats

Avoid leflunomide entirely in patients with existing hypertension or borderline BP, as it consistently worsens hypertension across multiple studies 3, 5. The cardiovascular protective effects of methotrexate extend beyond BP control—it reduces overall cardiovascular disease risk through powerful inflammation suppression 4. This dual benefit makes it particularly valuable in hypertensive RA patients who already face elevated cardiovascular risk.

The blood pressure improvements with methotrexate and hydroxychloroquine likely result from effective control of systemic inflammation, which is increasingly recognized as a driver of hypertension in RA patients 9, 10. Patients with RA demonstrate higher 24-hour ambulatory BP measurements despite similar office readings, with strong correlations between inflammatory mediators and nocturnal BP 10.